Q7ZUS1
Gene name |
vrk1 (zgc:56266) |
Protein name |
Serine/threonine-protein kinase VRK1 |
Names |
Vaccinia-related kinase 1 |
Species |
Danio rerio (Zebrafish) (Brachydanio rerio) |
KEGG Pathway |
dre:406694 |
EC number |
2.7.11.1: Protein-serine/threonine kinases |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q7ZUS1
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q7ZUS1-F1 | Predicted | AlphaFoldDB |
No variants for Q7ZUS1
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| No variants for Q7ZUS1 | |||||
3 associated diseases with Q7ZUS1
[MIM: 136000]: Adermatoglyphia (ADERM)
An autosomal dominant condition characterized by the lack of epidermal ridges on the palms and soles, which results in the absence of fingerprints, and is associated with a reduced number of sweat gland openings and reduced sweating of palms and soles. {ECO:0000269|PubMed:21820097, ECO:0000269|PubMed:24909267}. Note=The disease is caused by variants affecting the gene represented in this entry. Splice site mutations causing aberrant splicing of skin-specific isoform 3 are likely to exert a loss-of-function effect and are involved in ADERM. {ECO:0000269|PubMed:21820097, ECO:0000269|PubMed:24909267}.
[MIM: 129200]: Basan syndrome (BSNS)
An autosomal dominant form of adermatoglyphia associated with congenital facial milia, acral blistering, digital contractures, and nail abnormalities. Adermatoglyphia is defined by the lack of epidermal ridges on the palms and soles, which results in the absence of fingerprints. {ECO:0000269|PubMed:24664640, ECO:0000269|PubMed:26932190}. Note=The disease is caused by variants affecting the gene represented in this entry. Splice site mutations causing aberrant splicing of skin-specific isoform 3 are likely to exert a loss-of-function effect and are involved in BSNS. {ECO:0000269|PubMed:24664640, ECO:0000269|PubMed:26932190}.
[MIM: 181600]: Huriez syndrome (HRZ)
An autosomal dominant syndrome characterized by atrophic fibrosis of the skin of the limbs, nail hypoplasia, and palmoplantar keratoderma. Malignant degeneration of affected skin resulting in aggressive squamous cell carcinoma and early metastasis formation is a distinctive feature of the syndrome. {ECO:0000269|PubMed:29409814}. Note=The disease is caused by variants affecting the gene represented in this entry.
Without disease ID
- An autosomal dominant condition characterized by the lack of epidermal ridges on the palms and soles, which results in the absence of fingerprints, and is associated with a reduced number of sweat gland openings and reduced sweating of palms and soles. {ECO:0000269|PubMed:21820097, ECO:0000269|PubMed:24909267}. Note=The disease is caused by variants affecting the gene represented in this entry. Splice site mutations causing aberrant splicing of skin-specific isoform 3 are likely to exert a loss-of-function effect and are involved in ADERM. {ECO:0000269|PubMed:21820097, ECO:0000269|PubMed:24909267}.
- An autosomal dominant form of adermatoglyphia associated with congenital facial milia, acral blistering, digital contractures, and nail abnormalities. Adermatoglyphia is defined by the lack of epidermal ridges on the palms and soles, which results in the absence of fingerprints. {ECO:0000269|PubMed:24664640, ECO:0000269|PubMed:26932190}. Note=The disease is caused by variants affecting the gene represented in this entry. Splice site mutations causing aberrant splicing of skin-specific isoform 3 are likely to exert a loss-of-function effect and are involved in BSNS. {ECO:0000269|PubMed:24664640, ECO:0000269|PubMed:26932190}.
- An autosomal dominant syndrome characterized by atrophic fibrosis of the skin of the limbs, nail hypoplasia, and palmoplantar keratoderma. Malignant degeneration of affected skin resulting in aggressive squamous cell carcinoma and early metastasis formation is a distinctive feature of the syndrome. {ECO:0000269|PubMed:29409814}. Note=The disease is caused by variants affecting the gene represented in this entry.
5 regional properties for Q7ZUS1
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | SNF2, N-terminal | 513 - 785 | IPR000330 |
| domain | Helicase, C-terminal | 857 - 1010 | IPR001650 |
| domain | Ubiquitin system component CUE | 157 - 199 | IPR003892-1 |
| domain | Ubiquitin system component CUE | 251 - 294 | IPR003892-2 |
| domain | Helicase superfamily 1/2, ATP-binding domain | 493 - 687 | IPR014001 |
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.11.1 | Protein-serine/threonine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| Golgi stack | The set of thin, flattened membrane-bounded compartments, called cisternae, that form the central portion of the Golgi complex. The stack usually comprises cis, medial, and trans cisternae; the cis- and trans-Golgi networks are not considered part of the stack. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
3 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| protein serine kinase activity | Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate. |
| protein serine/threonine kinase activity | Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate. |
7 GO annotations of biological process
| Name | Definition |
|---|---|
| cell cycle | The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division. |
| cell division | The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells. |
| cellular response to DNA damage stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism. |
| Golgi disassembly | A cellular process that results in the breakdown of a Golgi apparatus that contributes to Golgi inheritance. |
| peptidyl-serine phosphorylation | The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine. |
| positive regulation of protein localization to chromatin | Any process that activates or increases the frequency, rate or extent of protein localization to chromatin. |
| signal transduction | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. |
15 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P29295 | HRR25 | Casein kinase I homolog HRR25 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) | PR |
| P35508 | CSNK1D | Casein kinase I isoform delta | Bos taurus (Bovine) | SS |
| Q5ZLL1 | CSNK1E | Casein kinase I isoform epsilon | Gallus gallus (Chicken) | SS |
| P48730 | CSNK1D | Casein kinase I isoform delta | Homo sapiens (Human) | SS |
| P49674 | CSNK1E | Casein kinase I isoform epsilon | Homo sapiens (Human) | EV |
| Q86Y07 | VRK2 | Serine/threonine-protein kinase VRK2 | Homo sapiens (Human) | PR |
| Q9DC28 | Csnk1d | Casein kinase I isoform delta | Mus musculus (Mouse) | PR |
| Q8BN21 | Vrk2 | Serine/threonine-protein kinase VRK2 | Mus musculus (Mouse) | PR |
| Q9JMK2 | Csnk1e | Casein kinase I isoform epsilon | Mus musculus (Mouse) | SS |
| Q06486 | Csnk1d | Casein kinase I isoform delta | Rattus norvegicus (Rat) | PR |
| P42169 | C03C10.2 | Putative casein kinase I C03C10.2 | Caenorhabditis elegans | PR |
| P34516 | K06H7.8 | Putative serine/threonine-protein kinase K06H7.1 | Caenorhabditis elegans | PR |
| Q6P647 | csnk1d | Casein kinase I isoform delta | Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) | SS |
| Q6P3K7 | csnk1db | Casein kinase I isoform delta-B | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| Q7T2E3 | csnk1da | Casein kinase I isoform delta-A | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MPPKKADGVK | KARAPAKRKL | AEEFPSGEVL | TDNAKKKWKL | GSAVGQGGFG | LLYLANEDSS |
| 70 | 80 | 90 | 100 | 110 | 120 |
| GPVTADAPYV | IKVEPSDNGP | LFSELKFYMR | AAKPDLIGAW | MKSKKMEYLG | VPKYWGSGFH |
| 130 | 140 | 150 | 160 | 170 | 180 |
| EKNGKRYRFM | VMDRFGTDLQ | KLFEGNGKKF | SRKLVLQLGL | RLLDILEYIH | DHEYVHADIK |
| 190 | 200 | 210 | 220 | 230 | 240 |
| ASNLLLSYTN | PNQVFLVDYG | LAYRYAPEGV | PKEYKEDPKR | CHDGTIEFTS | IDAHKGVSPS |
| 250 | 260 | 270 | 280 | 290 | 300 |
| RRADLEIMGY | CMIQWLCSRL | PWEDKLQDPL | YVRDSKLRCR | DNIDEFLKSC | FASGNIPAEM |
| 310 | 320 | 330 | 340 | 350 | 360 |
| GKFMQEVKVL | GYTDRPDYDK | LRGILQQGLK | SIGSTDDKKL | DFGVATNSTS | LPSVKTPKRK |
| 370 | 380 | 390 | 400 | 410 | 420 |
| KAEEKGQSAD | ETDSTPAKKR | RAPQKKEVNG | AKKTASPAKR | PVKKETQASS | EPAVKKSRGR |
| PKKNS |